Viking Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2012-01-01
- Employees
- 27
- Market Cap
- $6.8B
- Introduction
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.
Early study data puts Terns among obesity drug contenders
Terns Pharmaceuticals' experimental weight loss pill, TERN-601, helped obese participants lose over 5% of their body weight in a Phase 1 trial, prompting plans for mid-stage testing. The highest dose resulted in nearly 5% more weight loss than placebo, with moderate side effects primarily nausea. Terns aims to compete in the obesity drug market, currently dominated by injectables from Novo Nordisk and Eli Lilly, with a focus on oral alternatives.
Billionaires Are Buying Viking Therapeutics Stock Left and Right. Should You Follow Their Lead?
Wall Street is bullish on Viking Therapeutics (VKTX) due to successful clinical trials of its weight loss drug VK2735, which showed significant weight loss in patients. Billionaires Jeff Yass and Israel Englander have increased their stakes in the company. VK2735, a dual GLP-1 and GIP receptor agonist, outperformed competitors like Novo Nordisk's semaglutide and Eli Lilly's tirzepatide. Viking Therapeutics also has a promising drug, VK2809, for metabolic dysfunction-associated steatohepatitis (MASH). Upcoming catalysts include phase 3 trials for VK2735 and a phase 2 study of oral VK2735. Despite potential risks, Viking Therapeutics is considered a high-risk, high-reward investment.
© Copyright 2024. All Rights Reserved by MedPath